Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of uremic pruritus comprising an IL-31 antagonist as an active ingredient.

Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

Abstract: The present invention provides a substrateless double-sided adhesive sheet having an excellent optical inspection property by suppressing defects owing to foreign matters (such as oligomers) generated during a production process thereof which can exhibit a high productivity based on a high yield in a step of laminating a prepared adhesive sheet onto another member.

Abstract: A game device according to the present embodiment includes a camera as image pick-up means. An inner camera is accommodated in an upper housing. In addition, a microphone hole is provided in an inner surface of the upper housing so as to sense external sound through a microphone.

Abstract: A game device according to the present embodiment includes a camera as image pick-up means. An inner camera is accommodated in an upper housing. In addition, a microphone hole is provided in an inner surface of the upper housing so as to sense external sound through a microphone.

Abstract: A volume setting icon is provided with a slider for indicating a volume increasing from left toward right. A region in a direction of lower volume relative to a position corresponding to a current value, at which the slider is displayed, is identified as a volume low region, and a region in a direction of higher volume is identified as a volume high region. When the slider is selected, the slider can continuously be operated to move in any direction toward the volume low region and the volume high region. When the volume low region other than the slider is touched, the slider is instantaneously operated to move to a position corresponding to a touch position. When the volume high region other than the slider is touched, the slider is not instantaneously operated to move to a position corresponding to a touch position.

Abstract: The present invention provides a polyester film having excellent properties and being suitable as a film for brightness enhancement members which is capable of highly controlling orientation of a liquid crystal coated on a surface of the polyester film as a base material and can prevent the thus coated liquid crystal from suffering from occurrence of drawbacks such as evenness and formation of streaks. There is provided a polyester film for brightness enhancement members which has a laminated structure having a total thickness of 125 to 300 ?m and comprising no coating layer, in which at least one of outermost surfaces of the polyester film has a water droplet contact angle of 30 to 55° C., and the polyester film comprises an orientable liquid crystal coating layer subjected to no orientation treatment which is formed on the one outermost surface of the polyester film which surface has a water droplet contact angle of 30 to 55° C.

Abstract: A game device according to the present embodiment includes a camera as image pick-up means. An inner camera is accommodated in an upper housing. In addition, a microphone hole is provided in an inner surface of the upper housing so as to sense external sound through a microphone.

Abstract: A volume setting icon is provided with a slider for indicating a volume increasing from left toward right. A region in a direction of lower volume relative to a position corresponding to a current value, at which the slider is displayed, is identified as a volume low region, and a region in a direction of higher volume is identified as a volume high region. When the slider is selected, the slider can continuously be operated to move in any direction toward the volume low region and the volume high region. When the volume low region other than the slider is touched, the slider is instantaneously operated to move to a position corresponding to a touch position. When the volume high region other than the slider is touched, the slider is not instantaneously operated to move to a position corresponding to a touch position.